Mission Statement, Vision, & Core Values (2026) of Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Founded in 1992 by Professor Wu Yiling of the China Academy of Engineering, Shijiazhuang Yiling Pharmaceutical Co., Ltd. has grown into a leading force in combining traditional Chinese medicine with modern drug development, holding certifications from the US FDA, MHRA and China's NMPA and exporting to regulated markets worldwide; the company reports a product portfolio with over 10 patented TCM products and more than 20 formulations in clinical trials, has undertaken over 40 national and provincial projects (including National 973 and 863), and in 2021 achieved annual revenue exceeding USD 1.25 billion while employing over 16,000 staff globally-backed by an R&D strategy that invested about 12% of revenue in 2023, international sales representing 25% of revenue in 2023 with a target of 30% by 2025, distribution of over 500,000 doses of essential medicines to rural China in 2023, a reported 25% reduction in carbon emissions since 2020 on the way to a 50% cut by 2030, partnerships in more than 30 countries, and public-health contributions such as large-scale Lianhua Qingwen donations during the COVID-19 pandemic-all driven by the company's mission to "inherit and innovate, create welfare for mankind," its vision of global, affordable healthcare and sustainability, and core values centered on inheritance and innovation, integrity and dedication, and a people-oriented approach to talent and social responsibility.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) - Intro

• Founded: 1992 (Founder: Prof. Wu Yiling)
• Headquarters: Shijiazhuang, China
• Employees: >16,000 worldwide
• 2021 Revenue: > USD 1.25 billion
• Regulatory certifications: US FDA, UK MHRA, China NMPA (and other international approvals)
• Product IP: >10 patented TCM products; >20 formulations in clinical trials
• Therapeutic focus areas: cardiovascular, respiratory, oncology, diabetes (and supportive care)

• Deliver safe, effective, and scientifically validated TCM and pharmaceutical products that improve patient outcomes globally.
• Integrate traditional Chinese medical wisdom with modern R&D to create evidence-based therapies.
• Maintain stringent quality and regulatory compliance to ensure global market access.

• Be a global leader in integrative pharmaceuticals, recognized for combining TCM heritage with cutting-edge biomedical science.
• Expand international reach by securing approvals in major regulated markets and scaling manufacturing to meet global demand.
• Drive sustainable growth through innovation, with a pipeline that addresses major disease burdens worldwide.

• Scientific Rigor: Commit to evidence-based development and rigorous clinical validation of TCM and modern drugs.
• Quality First: Uphold GMP-level manufacturing and international regulatory standards (FDA, MHRA, NMPA).
• Patient-Centeredness: Prioritize safety, efficacy, and accessibility of therapies for diverse patient populations.
• Innovation: Invest in R&D, clinical trials, and translational science to expand the therapeutic pipeline (>20 formulations currently in trials).
• Integrity & Compliance: Ensure transparent governance, ethical research practices, and adherence to global regulatory frameworks.
• Global Collaboration: Forge partnerships and export finished drugs to regulated markets to broaden impact.

• R&D investment: Maintain and grow funding for clinical development of >20 active formulations, with priority in cardiovascular, respiratory, oncology, and diabetes.
• Regulatory expansion: Leverage existing US FDA/MHRA/NMPA certifications to accelerate approvals and market entry.
• Manufacturing scale: Support distribution of patented TCM products and finished drugs to regulated markets through certified production sites.
• Commercial performance: Target revenue growth beyond the 2021 benchmark of > USD 1.25 billion through pipeline commercialization and export expansion.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) - Overview

Mission: inherit and innovate, create welfare for mankind. Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) positions traditional Chinese medicine (TCM) at the center of a dual-path development model that combines TCM heritage with modern pharmaceutical science to improve global health and quality of life.

• Focus: industrialization and modernization of TCM alongside development of Western medicines.
• Commitment: long-term perseverance and dedication to public health and patient outcomes.
• R&D-driven: integration of clinical evidence, pharmaceutical engineering, and modern quality systems.

Strategic R&D and innovation are core to Yiling's mission. The company has participated in and led more than 40 national and provincial research projects, including contributions to National 973 and 863 Programs, reflecting sustained collaboration with state-level scientific initiatives.

• National/provincial projects undertaken: >40 (including National 973 and 863 Projects).
• Patented proprietary products: more than 10 newly developed patented drugs (examples include Tongxinluo Capsules and Lianhua Qingwen Capsules).
• Quality assurance: a comprehensive quality control system aligned with international standards (GMP, ISO-aligned processes and extensive batch release testing).

The company has an active public-health role, notably during the COVID-19 pandemic when it mobilized production and distribution of Lianhua Qingwen to support domestic and international relief efforts.

• COVID-19 donations and aid: large-scale donations of Lianhua Qingwen (medical supply donations to hospitals and communities, totaling in the order of magnitude of hundreds of thousands to millions of units during peak pandemic response).
• Cross-border relief: export and charitable distribution to multiple regions in need.

Vision: to be a global leader in evidence-based TCM and integrated medicine by scaling industrial production, accelerating innovation, and expanding international footprint while ensuring product safety and clinical efficacy.

• Globalization: expand regulatory approvals and market access across Asia, Europe, and emerging markets.
• Evidence generation: strengthen clinical trial pipelines and real-world evidence for TCM products.
• Sustainable growth: balance commercial scale-up with responsible manufacturing and community health contributions.

Core values guiding operations and culture:

• Patient-first ethics: prioritize safety, efficacy, and accessibility of therapies.
• Scientific rigor: rigorous R&D, regulatory compliance, and quality systems.
• Innovation with heritage: respect traditional formulas while applying modern pharmaceutical science.
• Social responsibility: active participation in public-health programs and charitable response during crises.
• Collaborative partnerships: working with government research programs, academic institutions, and global partners.

Key product and innovation highlights:

• Tongxinluo Capsules - patented cardioprotective TCM formulation developed and industrialized by Yiling.
• Lianhua Qingwen Capsules - one of Yiling's most widely recognized products, extensively used and donated during the COVID-19 response.
• Multiple pipeline candidates - ongoing clinical and preclinical programs derived from TCM principles combined with modern drug development techniques.

For historical context, ownership details, and an extended review of how the company operates and monetizes its portfolio, see: Shijiazhuang Yiling Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) - Mission Statement

• Deliver clinically effective, safe and affordable medicines blending TCM heritage with evidence-based modern R&D.
• Invest strategically in science and talent to maintain leadership in pharmaceutical innovation.
• Expand access to essential medicines for underserved and rural populations.
• Operate responsibly to minimize environmental impact and promote long-term sustainability.

• Lead the pharmaceutical industry through continuous innovation - R&D investments were approximately 12% of total revenue in 2023.
• Achieve significant global recognition and market penetration, targeting international markets to account for 30% of total revenue by 2025 (international sales were 25% in 2023).
• Promote health equity by making affordable healthcare accessible - distributed over 500,000 doses of essential medicines to rural areas in China in 2023.
• Attain ambitious sustainability targets: reduce carbon emissions by 50% by 2030 vs 2020; achieved a 25% reduction by 2023 through energy efficiency and waste management.
• Advance TCM-modern medicine integration with a strong pipeline - launched over 20 new products in the last fiscal year.
• Accelerate global footprint via partnerships in over 30 countries, targeting expansion into Europe and North America.

• Science-driven innovation: prioritize high-quality R&D and evidence-based integration of TCM and modern medicine.
• Patient-centric access: affordability, distribution to underserved regions, and commitment to public health.
• Integrity and compliance: transparent governance, regulatory adherence, and ethical commercialization.
• Sustainability: aggressive targets for emissions reduction, energy efficiency, and responsible waste management.
• Global collaboration: build and deepen international partnerships to deliver therapies worldwide.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) - Vision Statement

• Unity and Endeavor - fostering cross-functional collaboration across management, R&D, clinical, production, and marketing to accelerate product development and market delivery.
• Integrity and Dedication - maintaining compliance, ethical supply chains, and transparent reporting in all operations and investor relations.
• Inheritance and Innovation - combining TCM legacy with modern pharmaceutical R&D to expand therapeutic pipelines and evidence-based products.
• Create Welfare for Mankind - committing to broad public-health impact through affordable medicines, physician training, and community programs.

• High-quality team building: structured recruitment and development for management, technology, clinical research, production, and sales-targeting multidisciplinary competency growth.
• Six-character talent policy - cohesion, encouragement, and restraint-implemented to respect, cultivate, and maximize talent value via performance management, incentives, and disciplined career paths.
• Workforce metrics (latest disclosure): number of employees - 7,200; proportion in R&D/clinical roles - ~22%; annual training hours per employee - ~36 hours.

• Physician training and scholarships: annual grants and continuing education programs reaching >4,500 clinicians and medical students per year; funded scholarships totaling ¥6.5 million over recent cycles.
• Poverty alleviation: targeted infrastructure projects, vocational training, and local employment initiatives in multiple provinces-creating >2,400 sustained local jobs since program inception.
• Public-health contributions: large-scale distribution programs during epidemics and ongoing patient-access initiatives that reduced medicine cost barriers in underserved regions.

• Business resilience: maintained top-tier domestic TCM-pharmaceutical market share through diversified product portfolio and adaptive manufacturing capacity.
• Industry recognition: sustained placements and acknowledgements in international industry rankings (including recurring recognition in Pharm Exec 50-related industry lists) and participation among enterprises highlighted in Fortune Global 500-related supplier and partner mentions.
• Capital markets footprint: listed on the Shenzhen Stock Exchange (stock code 002603.SZ); sustained investor engagement and steady institutional holdings across domestic and international funds.

• Scale R&D investments to increase new molecular/TMC integrated product approvals by 30% over the next three years.
• Expand global footprint to 50+ export markets, strengthen regulatory dossiers in major regions.
• Deepen talent pipelines through targeted leadership programs, doubling senior clinical-scientist hires within two years.